



NDA 209511

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Innocoll Pharmaceuticals Limited
c/o ProPharma Group
1129 Twentieth Street NW
Suite 600
Washington, DC 20036

Attention: Dr. Rona LeBlanc-Rivera
Authorized U.S. Agent

Dear Dr. LeBlanc-Rivera:

Please refer to your new drug application (NDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (the Act) for Xaracoll (bupivacaine hydrochloride collagen-matrix) implant, which was approved on August 28, 2020.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for PMR 3928-1, which was deferred until May 31, 2024. Therefore, we are hereby notifying you that due to your failure to submit either a pediatric assessment or a request for a deferral extension by the original deferral expiration, you are not in compliance with federal law.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a **“DEFERRAL EXTENSION REQUESTED”** in your response.

While you are required to respond to this Non-Compliance letter as instructed above, you are not required to submit another deferral extension request, as we have received your July 15, 2024, deferral extension request, and it is currently under review.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at <https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a “**RESPONSE TO PREA NON-COMPLIANCE LETTER.**” To facilitate our review, submit this information to your NDA with a cross-reference letter to the investigational new drug application (IND) to which your protocol has been submitted.

If you have any questions, email Corey Estoll, Regulatory Project Manager, at Corey.Estoll@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Rigoberto Roca, MD
Director
Division of Anesthesiology, Addiction Medicine
and Pain Medicine
Office of Neuroscience
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

RIGOBERTO A ROCA
09/10/2024 06:54:34 PM